NextCure posts Q3 2025 financial results update

NextCure, Inc. filed a current report stating that it released its financial results for the quarter ended September 30, 2025.

Accepted by SEC EDGAR 11/05/2025 - 04:16 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

NextCure, Inc. filed a current report stating that it released its financial results for the quarter ended September 30, 2025. On November 5, 2025, the company issued a press release with these quarterly results and attached it as Exhibit 99.1. The report clarifies that this press release is being furnished, not filed, which affects how it is treated under securities laws.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NextCure (NXTC) report in this Form 8-K?

NextCure, Inc. reported that it issued a press release announcing its financial results for the quarter ended September 30, 2025, and furnished that release as Exhibit 99.1.

When did NextCure (NXTC) release its quarterly financial results?

NextCure released its quarterly financial results on November 5, 2025, as stated in the press release referenced in the report.

Which period do the NextCure (NXTC) financial results in this 8-K cover?

The financial results discussed in the referenced press release cover the quarter ended September 30, 2025.

How is the NextCure (NXTC) earnings press release treated under securities laws?

The company states that the information in Item 2.02, including Exhibit 99.1, is being furnished and not filed for purposes of Section 18 of the Exchange Act.

What exhibits are included with this NextCure (NXTC) Form 8-K?

The report includes Exhibit 99.1, which is the press release dated November 5, 2025, and Exhibit 104, the cover page interactive data file in inline XBRL format.

Who signed the Form 8-K for NextCure (NXTC)?

The Form 8-K was signed on behalf of NextCure, Inc. by Steven P. Cobourn, Chief Financial Officer, dated November 5, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001661059false00016610592025-11-052025-11-05

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025

NextCure, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation) 001-38905
(Commission File Number) 47-5231247
(IRS Employer Identification No.)

​ ​
9000 Virginia Manor Road, Suite 200 Beltsville, Maryland		20705
(Address of principal		(Zip Code)
executive offices)

Registrant's telephone number, including area code: (240) 399-4900

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	NXTC	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02Results of Operations and Financial Condition

On November 5, 2025, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025.  The company is furnishing a copy of the press release, which is attached hereto as exhibit 99.1.

​

The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

​

​

​

​

Item 9.01Financial Statements and Exhibits

​

d) Exhibits

​

Exhibit No. Description

99.1 Press Release issued by NextCure, Inc. dated November 5, 2025

104 Cover Page Interactive Data File (formatted as inline XBRL).

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

November
Dated: November 5, 2025	NEXTCURE, INC. ​
	By:	/s/ Steven P. Cobourn
	Name:	Steven P. Cobourn
	Title:	Chief Financial Officer

​

​

​

​

​